Join to view full profile
1240 S Cedar Crest BlvdSuite 401Allentown, PA 18103
Phone+1 610-402-7880
Dr. Nair is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Suresh Nair is an oncology specialist based in Allentown, PA. He completed his medical education at Sidney Kimmel Medical College at Thomas Jefferson University, followed by a residency in Internal Medicine at Geisinger Health System, and a fellowship in Hematology and Medical Oncology at UPMC Medical Education. He has contributed to the field through multiple publications, including works in NEJM, BMJ Case Reports, Nature Medicine, Journal of Clinical Oncology, Clinical Cancer Research, and Cancer Research Communications. His participation in clinical trials includes studies on melanoma and lung cancer, among others. Dr. Nair has received several recognitions, including CMS Meaningful Use Certifications and the Patient-Centered Specialty Practice Recognition from the National Committee for Quality Assurance. Dr Nair serves as the Chair of ABIM Medical Oncology.
Education & Training
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 1987 - 1990
Geisinger Health System (Danville)Residency, Internal Medicine, 1984 - 1987
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1984
Certifications & Licensure
PA State Medical License 1985 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MOSAIQ, Elekta - IMPAC Medical Systems, Inc., 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification MOSAIQ, Elekta - IMPAC Medical Systems, Inc., 2012, 2014-2017
- Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
Clinical Trials
Publications & Presentations
PubMed
- YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 ...James W Smithy, Victoria Ciallella, Claire Thant, Hannah L Kalvin, Jaykumar Thumar
Journal of the National Comprehensive Cancer Network. 2026-03-31 - YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 ...James W Smithy, Victoria Ciallella, Claire Thant, Hannah L Kalvin, Jaykumar Thumar
Journal of the National Comprehensive Cancer Network. 2026-03-31 - Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.Farshad Nassiri, Vikas Patil, Leeor S Yefet, Olivia Singh, Jeff Liu
Nature Medicine. 2025-09-01
Press Mentions
Here Is What You Need to Know About LVHN’s New Personalized Cancer CenterSeptember 30th, 2025- LVHN Participating in Potentially Groundbreaking Pancreatic Cancer Vaccine Trial. What You Need to KnowAugust 19th, 2024
- Navigating the Complexities of Oncology: Staying Current Amidst Rapid InnovationsAugust 16th, 2024
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
